1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,900 | 7,300 | 27.11. | |
| 6,950 | 7,250 | 27.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11. | Goldman Sachs initiates Keymed Biosciences stock with Buy rating | 1 | Investing.com | ||
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.11. | Goldman Sachs: Kaufempfehlung für Keymed Biosciences zum Start der Analyse | - | Investing.com Deutsch | ||
| 25.09. | KEYMED BIO-B (02162): 2025 INTERIM REPORT | - | HKEx | ||
| 27.08. | Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum | 248 | PR Newswire | CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.
Financially... ► Artikel lesen | |
| 26.08. | KEYMED BIO-B (02162): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025; AND RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY ... | 1 | HKEx | ||
| 14.08. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | 4 | HKEx | ||
| 26.06. | KEYMED BIO-B (02162): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025 | - | HKEx | ||
| 19.06. | KEYMED BIO-B (02162): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 19.06. | KEYMED BIO-B (02162): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE | - | HKEx | ||
| 13.06. | Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine | 776 | PR Newswire | CHENGDU, China, June 13, 2025 /PRNewswire/ -- On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases... ► Artikel lesen | |
| 11.06. | KEYMED BIO-B (02162): (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP ... | 1 | HKEx | ||
| 27.04. | Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt | 134 | PR Newswire | CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder das "Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein... ► Artikel lesen | |
| 25.04. | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors | 360 | PR Newswire | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed... ► Artikel lesen | |
| 07.04. | Keymed Biosciences: Daten aus Phase-III-Studie zu Stapokibart gegen saisonale allergische Rhinitis in Nature Medicine veröffentlicht | 301 | PR Newswire | CHENGDU, China, 7. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder "Unternehmen") gab heute bekannt, dass die renommierte medizinische... ► Artikel lesen | |
| 05.04. | Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine | 747 | PR Newswire | CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published... ► Artikel lesen | |
| 26.03. | Keymed Biosciences Announces Annual Results of 2024 | 184 | PR Newswire | CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate... ► Artikel lesen | |
| 08.02. | Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis | 798 | PR Newswire | CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the... ► Artikel lesen | |
| 23.12.24 | Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis | 346 | PR Newswire | CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 40,390 | 0,00 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| NUVALENT | 109,06 | 0,00 % | Nuvalent closes $500 million public offering of common stock | ||
| VERA THERAPEUTICS | 33,330 | 0,00 % | Why Vera Therapeutics Stock Crushed it Today | ||
| AVIDITY BIOSCIENCES | 71,59 | +0,04 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| OLEMA PHARMACEUTICALS | 28,110 | 0,00 % | Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
| PRAXIS PRECISION MEDICINES | 188,52 | -0,01 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| ADMA BIOLOGICS | 19,150 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| IMMUNOVANT | 23,700 | 0,00 % | Immunovant, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 25,030 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 21,180 | +0,05 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| TREVI THERAPEUTICS | 13,295 | +0,04 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026
Company ended... ► Artikel lesen | |
| QIAGEN | 41,445 | -0,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ARCELLX | 73,24 | -0,01 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| NURIX THERAPEUTICS | 17,200 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 30,950 | 0,00 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week |
KEYMED BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,950 Euro und damit +5,30 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.